Type6 Therapeutics
3 known investors
Find your way into Type6 Therapeutics
44 people in our graph share verified history with the Type6 Therapeutics team — schools, employers, funds. One of them is your warm intro.
Amanda Josephunlockedknows Jeffrey Ohren · together at University of Michigan Medical School (overlapped)
×2knows the team · via University of Michigan Medical School
knows the team · via The University of Toledo
×7knows the team · via Northern Kentucky University
knows the team · via Warner Lambert / Parke-Davis, Ann Arbor, MI
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
Founders & leadership
GK
Gert KissinCo-founder & CEO
AB
Alexander BridgesCo-founder, CSO, VP Chemistry
JO
Jeffrey OhreninCo-founder, VP BiologyHe previously led structural biology research that elucidated the mechanism of the kinase inhibitor trametinib, and has published extensively in protein chemistry and structural biology with a focus on kinase-targeted drug design.
MO
Mihail ObroceaHead of Development
RS
Robert SonsHead of Operations
Investors · 3
Frequently asked questions
- What does Type6 Therapeutics do?
- Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
- Who founded Type6 Therapeutics?
- Type6 Therapeutics was founded by Gert Kiss, Alexander Bridges, Jeffrey Ohren.
- Who are Type6 Therapeutics's investors?
- Type6 Therapeutics's investors include Artis Ventures, BoxOne Ventures, OMX Ventures.